Werewolf Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Werewolf Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Werewolf Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$16.7M, a 101% decline year-over-year.
  • Werewolf Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$62.1M, a 66.6% decline year-over-year.
  • Werewolf Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$37.4M, a 30.6% increase from 2022.
  • Werewolf Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$53.8M, a 7.66% decline from 2021.
  • Werewolf Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$50M, a 232% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$62.1M -$16.7M -$8.39M -101% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$53.7M -$17.2M -$12.2M -238% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$41.6M -$16.2M -$4.21M -35.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$37.4M -$12M -$73K -0.61% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$37.3M -$8.29M +$3.66M +30.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$41M -$5.1M +$9.5M +65.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$50.4M -$12M +$3.36M +21.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$53.8M -$11.9M +$5.94M +33.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$59.7M -$11.9M +$1.82M +13.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$61.6M -$14.6M -$3.67M -33.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$57.9M -$15.3M -$7.91M -106% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$50M -$17.9M -$10.5M -141% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$39.5M -$13.8M -$7.69M -127% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$31.8M -$10.9M -$13.2M -584% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$18.6M -$7.44M -$3.61M -94.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$15M -$7.4M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$6.07M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $2.26M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$3.83M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.